Avacincaptad Pegol
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Idiopathic Polypoidal Choroidal Vasculopathy
Conditions
Idiopathic Polypoidal Choroidal Vasculopathy
Trial Timeline
Mar 12, 2015 → Oct 23, 2015
NCT ID
NCT02397954About Avacincaptad Pegol
Avacincaptad Pegol is a phase 2 stage product being developed by Astellas Pharma for Idiopathic Polypoidal Choroidal Vasculopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT02397954. Target conditions include Idiopathic Polypoidal Choroidal Vasculopathy.
What happened to similar drugs?
20 of 20 similar drugs in Idiopathic Polypoidal Choroidal Vasculopathy were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06970665 | Approved | Recruiting |
| NCT05536297 | Phase 3 | Completed |
| NCT02686658 | Phase 2/3 | Completed |
| NCT02397954 | Phase 2 | Completed |
| NCT00950638 | Phase 1 | Completed |
| NCT00709527 | Phase 1 | Completed |
Competing Products
20 competing products in Idiopathic Polypoidal Choroidal Vasculopathy